Research programme: antibacterials - AvidBiotics

Drug Profile

Research programme: antibacterials - AvidBiotics

Alternative Names: Acinetobacter infection therapy - AvidBiotics; Clostridium difficile infection therapy - AvidBiotics; Escherichia coli infection therapy - AvidBiotics; Pseudomonas aeruginosa infection therapy - AvidBiotics; Yersinia pestis therapy - AvidBiotics; Avidocin therapeutics

Latest Information Update: 20 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AvidBiotics Corp.
  • Class Bacteriocins; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acinetobacter infections; Clostridium infections; Escherichia coli infections; Shiga-toxigenic Escherichia coli infections; Yersinia infections
  • No development reported Gram-negative infections; Pseudomonal infections

Most Recent Events

  • 05 Oct 2012 No development reported - Preclinical for Gram-negative infections in USA (unspecified route)
  • 05 Oct 2012 No development reported - Preclinical for Pseudomonal infections in USA (Topical)
  • 05 Oct 2012 Preclinical trials in Clostridium infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top